CEO and Head of Research
Dr. Karsdal joined Nordic Bioscience in 2001 and rose to CEO in 2010. Karsdal is a visionary leader known for his deep expertise and commitment to biomarker development, the extracellular matrix and disease biology. Dr. Karsdal has published more than 600 peer-reviewed articles and has presented at numerous international scientific conferences. Dr. Karsdal oversees several major partnerships as well as over 150 collaborators in Copenhagen.
H-index: 89. i10-index: 479. Citations: 29704 as of March 2023.
CTO and Director of ImmunoScience
Dr. Bay-Jensen has been with Nordic Bioscience since 2008 - she started as a post-doc and has since been appointed Director of ImmunoScience and Chief Technology Officer (CTO). Through hard work, inventive mentality, and leadership, she has developed novel biomarkers that support precision medicine - a journey that continues. As a researcher, she focuses primarily on biomarkers for rheumatic diseases, which she has worked on for two decades.
H-index: 58. i10-index: 180. Citations: 9708 as of March 2023.
Director of Fibrosis, Hepatic and Pulmonary Research
Dr. Leeming joined Nordic Bioscience in 2004 and assumed the position as Director of Fibrosis in 2010. Her focus is on the development of serologically assessed markers to evaluate the extracellular matrix remodelling in patients with pulmonary or hepatic fibrosis for diagnosis or pharmacodynamic evaluation. Dr.Leeming is a principle inventor of PRO-C3 assay, a fibrogenesis marker used in multiple clinical trial studies. She has 150+ peer-reviewed publications.
H-index: 56. I10-index: 155. Citations: 9744 as of March 2023.
Director of Endocrinology
Dr. Henriksen joined Nordic Bioscience in 2002 and assumed the position of director of endocrinology in 2018. His research focuses on the identification and development of novel peptide therapies for metabolic diseases such as obesity, NASH, and type 2 diabetes, and has led to the patenting and development of two families of peptides, KBPs and OXMs, which are rapidly moving toward clinical development.
H-index: 60, i10-index: 151, Citations 11985 as of March 2023.
Director of Fibrosis, Renal and Cardiovascular Research
Dr. Genovese joined Nordic Bioscience in 2011 and since 2014 has led a group focused on the application of markers for ECM remodeling in renal and cardiovascular disease. Her group's activities range from biomarker discovery and development to clinical and preclinical validation of biomarkers in various chronic kidney diseases (CKD, DKD, IgAN, ADPKD, kidney transplantation) and cardiovascular diseases (HFpEF, atherosclerosis, myocardial infarction, atrial fibrillation).
H-index: 27. i10-index: 40. Citations: 2819 as of March 2023.
Director of Oncology
Dr. Willumsen joined Nordic Bioscience in 2012 and assumed the position of department head in oncology in 2016. His research group focuses on the development of blood-based biomarkers to quantify tumor matrix in serum of cancer patients to understand pharmacodynamics/efficacy/resistance mechanisms of treatments. The group's research activities range from biomarker discovery to preclinical and clinical validation of results. In 2022, Dr. Willumsen was appointed as Director of Oncology.
H-index: 21. i10-index: 40. Citations: 1453 as of March 2023.
Chief Laboratory Officer, Head of Clinical Laboratory
Dr. Manon-Jensen has been with Nordic Bioscience for more than 8 years, where she was the principal investigator of hemophilia research, discovering novel biomarkers and utilizing her knowledge in the clinical needs for biomarker usage in clinical trials. Today, as the Head of Clinical Laboratory, she is responsible for the daily operations and business of our CAP-certified and CLIA-compliant laboratory. Her responsibilities include overseeing the measurements we deliver to our customers, QA, biobank, project and data management, LIMS, and custom/CLSI validations.
Dr. Manon-Jensen spearheads the only CAP laboratory in Scandinavia and works to differentiate our services from protein array service providers. With her leadership, our lab subscribes to the highest quality standards, and among other things, we are partnering with Roche and advancing IDS i10 platform investments.
H-index: 19. i10-index: 28. Citations: 2249 as of March 2023.
Project Director, Clinical Laboratory
Kishwar joined Nordic Bioscience in 2011 after graduating from the Technical University of Denmark. Since 2013 she has been heading the biomarker laboratory associated with the patented tests developed by Nordic Bioscience. Today she leads a team of more than 30 technicians and dedicated project managers providing high quality laboratory services covering all aspects of testing programs for our key customers in the biotech and pharmaceutical industry.
Head of Data Science
Dr. Bager joined Nordic Bioscience in 2012 - she started as a PhD student and was appointed Head of Datascience in 2019. As Head of Datascience, she and her team focus heavily on biomarker data work and how it can be used to support precision medicine.
H-index: 13. i10-index: 17. Citations: 754 as of March 2023.
Please don't hesitate to contact us if you have any questions or other inquiries.